비교리스트

 카트 문의
시장보고서
상품코드
1546190

세계의 방사면역측정법 시장

Radioimmunoassays
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

방사면역측정법 세계 시장은 2030년까지 5억 8,710만 달러에 이를 전망

2023년에 4억 7,090만 달러로 추정된 방사면역측정법 세계 시장은 2030년에는 5억 8,710만 달러에 이르고, 분석 기간인 2023-2030년간 CAGR 은 3.2%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 방사면역측정법 시약＆키트는 CAGR 3.4%를 나타내고, 분석 기간 종료까지 4억 5,870만 달러에 이를 것으로 예측됩니다. 방사면역측정법 분석 장비 부문의 성장률은 분석 기간중 CAGR 2.6%로 추정됩니다.

미국 시장은 1억 2,560만 달러로 추정, 중국은 CAGR2.7%로 성장 예측

미국 방사면역측정법 시장은 2023년에 1억 2,560만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 2.7%로 성장을 지속하여, 2030년에는 시장 규모 9,170만 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.1%와 2.6%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

세계 방사성동위원소 분석 시장 - 주요 동향 및 촉진요인 요약

방사면역측정법 : 진단 검사에 혁명을 불러일으키다

방사면역측정법(RIA)은 일반적으로 혈액이나 소변과 같은 시료에서 특정 항원이나 호르몬의 농도를 측정하는 데 사용되는 고감도 실험실 기술입니다. 이 방법은 표적 분자에 결합하는 방사성 표지 항원 또는 항체를 사용하여 표적 물질을 정확하게 정량할 수 있으며, 임상 실험실에서 호르몬 장애, 감염, 암을 포함한 다양한 질병을 감지하고 모니터링하는 데 널리 사용되고 있습니다. 높은 민감도와 특이성을 가진 이 기술은 인슐린, 갑상선 호르몬, 생식 호르몬과 같은 낮은 수준의 호르몬을 검출하고 종양 마커 및 기타 바이오마커를 측정하는 데 특히 유용하며, RIA는 질병 진단, 치료 계획 및 모니터링에 필수적인 정확하고 신뢰할 수 있는 결과를 제공함으로써 진단 검사에 혁명을 일으켰습니다, 진단 검사에 혁명을 일으켰습니다.

기술의 발전은 어떻게 방사성동위원소 분석을 개선하고 있는가?

기술의 발전은 방사성동위원소 분석의 성능, 안전성 및 편의성을 크게 향상시켜 다양한 진단 응용 분야에 효과적입니다. 방사성 동위원소 라벨링의 혁신은 RIA 시약의 안정성과 민감도를 향상시켜 보다 정확하고 일관된 결과를 가능하게 했습니다. 자동화된 RIA 시스템의 개발은 검사 과정을 간소화하여 분석 준비 및 분석에 필요한 시간과 노력을 줄이고 인적 오류의 위험을 최소화하고 있습니다. 분석기 소형화 및 마이크로플레이트 형태의 사용으로 RIA의 처리량이 향상되어 여러 샘플을 동시에 분석할 수 있게 되어 실험실 효율성이 향상되었습니다. 또한 RIA와 효소면역측정법(EIA), 화학발광분석법 등 다른 진단 기술과의 통합을 통해 검출 및 정량화할 수 있는 분석물의 범위가 확대되어 보다 종합적인 진단 정보를 얻을 수 있게 되었습니다. 이러한 기술적 발전은 전 세계 임상 실험실에서 첨단 RIA 시스템의 채택을 촉진하고 있습니다.

의료 진단에서 방사성임상시험의 주요 용도와 장점은 무엇인가?

방사면역측정법은 다양한 진단 응용 분야에 사용되며 의료 검사의 정확성, 신뢰성 및 효율성을 향상시키는 여러 가지 이점을 제공합니다. 내분비학에서 RIA는 당뇨병, 갑상선 질환, 생식기 질환과 같은 환자의 호르몬 수치를 측정하는 데 필수적이며 진단 및 치료 계획에 중요한 정보를 제공합니다. 종양학에서 RIA는 종양 마커를 감지하고 암 치료의 효과를 모니터링하는 데 사용되어 조기 개입과 개별화 된 치료 접근 방식을 가능하게합니다. 이 기술은 감염 검사에도 유용하여 환자 샘플에서 바이러스 및 박테리아 항원의 존재를 감지하여 감염을 신속하게 진단하고 관리하는 데 도움이 될 수 있습니다. 또한 RIA는 약동학에서 혈액 내 약물 농도를 측정하여 적절한 용량을 보장하고 치료 반응을 모니터링하는 데 사용되며, RIA의 주요 장점은 높은 민감도, 특이성 및 저농도 분석물 검출 능력으로 임상 진단에 필수적인 도구가되었습니다.

방사면역측정법 시장의 성장을 가속하는 요인은 무엇인가?

방사면역측정법 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 암, 당뇨병, 호르몬 이상과 같은 만성 질환의 유병률 증가는 효과적인 관리를 위해 정밀한 진단 검사가 필요하기 때문에 중요한 촉진요인으로 작용하고 있습니다. 방사성 동위원소 표지, 자동화, 분석기 소형화 등의 기술 발전은 RIA 시스템의 성능과 효율성을 향상시켜 시장 성장을 가속하고 있습니다. 맞춤형 의료와 표적치료에 대한 수요 증가는 RIA의 채택을 더욱 촉진하고 있습니다. 이러한 기술은 개인화된 치료 계획을 위한 중요한 정보를 제공하기 때문입니다. 또한, RIA는 감염 검사 및 약동학 등의 분야에서 RIA의 용도가 확대되고 있으며, 의료 서비스 제공업체가 보다 정확하고 신뢰할 수 있는 진단 도구를 찾고 있는 것도 시장 성장에 기여하고 있습니다. 진단 정확도 향상과 의료 비용 절감에 대한 관심이 높아지면서 임상 실험실에서 첨단 RIA 시스템 도입이 증가하고 있습니다. 이러한 요인들은 진단 기술의 지속적인 혁신과 함께 방사성동위원소 분석 시장의 지속적인 성장을 견인하고 있습니다.

조사 대상 기업 예(주목 44개사)

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 24.09.10

Global Radioimmunoassays Market to Reach US$587.1 Million by 2030

The global market for Radioimmunoassays estimated at US$470.9 Million in the year 2023, is expected to reach US$587.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Radioimmunoassay Reagents & Kits, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$458.7 Million by the end of the analysis period. Growth in the Radioimmunoassay Analyzers segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.6 Million While China is Forecast to Grow at 2.7% CAGR

The Radioimmunoassays market in the U.S. is estimated at US$125.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$91.7 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Radioimmunoassays Market - Key Trends and Drivers Summarized

Radioimmunoassays: Revolutionizing Diagnostic Testing

Radioimmunoassays (RIAs) are highly sensitive laboratory techniques used to measure the concentration of specific antigens or hormones in a sample, typically blood or urine. The method involves the use of radioactively labeled antigens or antibodies that bind to the target molecule, allowing for precise quantification of the substance of interest. RIAs are widely used in clinical laboratories for the detection and monitoring of various medical conditions, including hormonal disorders, infectious diseases, and cancer. The technique's high sensitivity and specificity make it particularly valuable for detecting low levels of hormones, such as insulin, thyroid hormones, and reproductive hormones, as well as for measuring tumor markers and other biomarkers. RIAs have revolutionized diagnostic testing by providing accurate and reliable results that are critical for disease diagnosis, treatment planning, and monitoring.

How Are Technological Advancements Enhancing Radioimmunoassays?

Technological advancements have significantly improved the performance, safety, and convenience of radioimmunoassays, making them more effective for a wide range of diagnostic applications. Innovations in radioisotope labeling have enhanced the stability and sensitivity of RIA reagents, allowing for more accurate and consistent results. The development of automated RIA systems has streamlined the testing process, reducing the time and labor required for assay preparation and analysis, while also minimizing the risk of human error. Advances in assay miniaturization and the use of microplate formats have increased the throughput of RIAs, enabling the simultaneous analysis of multiple samples and improving laboratory efficiency. Additionally, the integration of RIA with other diagnostic techniques, such as enzyme immunoassays (EIAs) and chemiluminescent assays, has expanded the range of analytes that can be detected and quantified, providing more comprehensive diagnostic information. These technological improvements are driving the adoption of advanced RIA systems in clinical laboratories worldwide.

What Are the Key Applications and Benefits of Radioimmunoassays in Medical Diagnostics?

Radioimmunoassays are used in a wide range of diagnostic applications, offering numerous benefits that enhance the accuracy, reliability, and efficiency of medical testing. In endocrinology, RIAs are essential for measuring hormone levels in patients with conditions such as diabetes, thyroid disorders, and reproductive health issues, providing critical information for diagnosis and treatment planning. In oncology, RIAs are used to detect tumor markers and monitor the effectiveness of cancer therapies, allowing for early intervention and personalized treatment approaches. The technique is also valuable in infectious disease testing, where it can detect the presence of viral or bacterial antigens in patient samples, aiding in the rapid diagnosis and management of infections. Additionally, RIAs are used in pharmacokinetics to measure drug levels in the blood, ensuring appropriate dosing and monitoring therapeutic responses. The primary benefits of RIAs include their high sensitivity, specificity, and ability to detect low concentrations of analytes, making them indispensable tools in clinical diagnostics.

What Factors Are Driving the Growth in the Radioimmunoassays Market?

The growth in the Radioimmunoassays market is driven by several factors. The increasing prevalence of chronic diseases, such as cancer, diabetes, and hormonal disorders, is a significant driver, as these conditions require precise diagnostic testing for effective management. Technological advancements in radioisotope labeling, automation, and assay miniaturization are also propelling market growth by enhancing the performance and efficiency of RIA systems. The rising demand for personalized medicine and targeted therapies is further boosting the adoption of RIAs, as these techniques provide critical information for individualized treatment planning. Additionally, the expanding applications of RIAs in areas such as infectious disease testing and pharmacokinetics are contributing to market growth, as healthcare providers seek more accurate and reliable diagnostic tools. The growing focus on improving diagnostic accuracy and reducing healthcare costs is also supporting the adoption of advanced RIA systems in clinical laboratories. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Radioimmunoassays market.

Select Competitors (Total 44 Featured) -

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Radioimmunoassays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Sensitive and Specific Diagnostic Tests Propels Market Growth
    • Increasing Use in Clinical and Research Laboratories Expands Addressable Market Opportunity
    • Technological Advancements in Radioimmunoassay Techniques Strengthen Market Position
    • Growing Focus on Early Disease Detection and Monitoring Drives Adoption of Radioimmunoassays
    • Surge in Demand for Hormone and Tumor Marker Testing Generates New Opportunities
    • Development of Automated and High-Throughput Assay Systems Sustains Market Growth
    • Expanding Applications in Endocrinology and Oncology Throws Spotlight on Market Potential
    • Growth in Personalized Medicine and Targeted Therapies Spurs Demand for Radioimmunoassays
    • Rising Adoption of Radioimmunoassays in Academic and Research Institutions Propels Market Expansion
    • Surge in Demand for Radioimmunoassays in Infectious Disease Testing Expands Market Horizons
    • Growing Awareness of the Benefits of Radioimmunoassays in Rare Disease Diagnosis Drives Market Adoption
    • Innovations in Radioactive Labeling and Detection Technologies Generate New Market Opportunities
    • Rising Demand for Radioimmunoassays in Emerging Healthcare Markets Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Radioimmunoassays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제